A Aforeworn
Forewarned is forearmed.
Home › Niches › Pharmaceutical Manufacturing (FDA/DEA) › Change
High urgency

FDA cites drug firms for CGMP violations, failing to provide records - RAPS

Detected July 16, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

FDA has cited drug firms for CGMP violations and failure to provide records, indicating increased enforcement of record-keeping requirements under current good manufacturing practices.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; ongoing compliance required.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

FDA is intensifying scrutiny of CGMP compliance, specifically regarding record-keeping and documentation practices.

Who it affects

Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)

What you must do

Review and strengthen record-keeping procedures to ensure all required records are readily available for FDA inspection.

Deadline

Immediately; ongoing compliance required.

Source: https://news.google.com/rss/articles/CBMipAFBVV95cUxQV2FzSEwzNktVYjVBSS1UY01ibUxEaW9HUzZ6Nkpfd2xOM0V5bmpDUEZ0T01Hcm1nZEw0WTVaNWJmNVFKZkdtdVV5Z01qQzhjSHE4elp5aE4xS1dKMllyQXRyaUo5alJlaTVvUUE3dzFUTklmeWVHTjF5elhuczFQdDhpMm5LS3dhZjRyeUx1QVdsOElDN3l5VjIzNEVtcDlaZkswRg?oc=5

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)